Pafolacianine
- TRADE NAME: Cytalux (On Target Labs)
- INDICATIONS: Optical imaging agent for use in fluoresence-guided surgery. Indicated in adult patients with ovarian cancer.
- SYNONYM: Pafolacianine sodium
- CLASS: Diagnostic aid, Optical imaging agent
- HALF-LIFE: 0.4 hours
FDA APPROVAL DATE: 11/29/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
Pafolacianine may cause fetal harm when administered to a pregnant woman.
Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy prior to administration of pafolacianine. Discontinue folate, folic acid, or folate containing supplements 48 hours before administration of pafolacianine. Pafolacianine is not approved for use in patients with cancer in the lung.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
GASTROINTESTINAL/HEPATIC.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric